Company profile

Merz Therapeutics

Privately held: no public share price

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Fampridine(Ampyra / Fampyra)
Approved
Undisclosed / early pipeline · Voltage-gated potassium channel (Kv) · Voltage-gated potassium channels (Kv1/Shaker/KCNA family)Small molecule
Multiple Sclerosis
Inbrija (CVT-301)(Inbrija)
Approved
dopamine precursorSmall molecule
Parkinson's Disease

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.